RE:News FlashI think you need to keep in mind the liberalizing policies at the FDA which are designed to get drugs to market faster. The FDA clearly sees something here. The safety profile is so promising, and the benefits on top of top standard of care are very real. | believe going forward the FDA will exercise far greater discretion than in the past to approve drugs that had 'failed' trials, as long as those trials proved safety and likelihood of some measurable improvement over current top standard of care. RVX has done both those things despite the technical 'failed trials'. There is very substantial value to the 20 years of research in this company. So much so that it was amazing to see ORI convert the debenture that could have given them full ownership of IP, in favor of shares at market price, not even with warrants attached as any standard PP would offer. ORI became a regular common shareholder like all of us (but with inside knowledge, unlike anyone here). There is plenty of value. I believe the time which has elapsed testifies to the complexities of putting the deal together, but elapsed time does not say no deal will be done.